Literature DB >> 11376026

Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer.

J G Stone1, D Robertson, R S Houlston.   

Abstract

Colorectal cancers with DNA mismatch repair (MMR) gene mutations characteristically display a high rate of replication errors in simple repetitive sequences detectable as microsatellite instability (MSI). Most are the result of somatic MMR dysfunction; however, a subset are caused by germline mutations. The availability of commercial antibodies for MSH2 and MLH1 [corrected] offers an alternative strategy to molecular methods for identifying MMR deficient cancers. To evaluate immunohistochemistry, MLH1 and MSH2 expression was studied using monoclonal antibodies in formalin fixed, paraffin wax embedded cancers. The immunohistochemical staining patterns of 23 cancers displaying MSI, including four cases with germline mutations, were compared with 23 microsatellite stable (MSS) cancers. All MSS cancers exhibited staining with both antibodies. Twenty two of the MSI cases showed absent MMR expression with either anti-MSH2 or anti-MLH1 [corrected]. The high sensitivity and predictive value of immunohistochemistry in detecting MMR deficiency offers a method of discriminating between MSI and MSS cancers caused by MSH2 and MLH1 [corrected] dysfunction. The application and suitability of immunohistochemistry for the detection of MSI and as a strategy for prioritising the mutational analysis of MMR genes in routine clinical practice is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376026      PMCID: PMC1731447          DOI: 10.1136/jcp.54.6.484

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

Review 1.  The utility of immunohistochemical detection of DNA mismatch repair gene proteins.

Authors:  Jinru Shia; Nathan A Ellis; David S Klimstra
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

Review 2.  [Prognostic marker profiles for risk of distant metastases in colorectal cancer].

Authors:  J Neumann; S Reu; T Kirchner
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

3.  MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions.

Authors:  Jérémie H Lefevre; Chrystelle Colas; Florence Coulet; Carolina Bonilla; Najat Mourra; Jean-Francois Flejou; Emmanuel Tiret; Walter Bodmer; Florent Soubrier; Yann Parc
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

4.  Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients.

Authors:  Francesc Balaguer; Judith Balmaña; Sergi Castellví-Bel; Ewout W Steyerberg; Montserrat Andreu; Xavier Llor; Rodrigo Jover; Sapna Syngal; Antoni Castells
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

Review 5.  [Molecular pathology of colorectal cancer].

Authors:  J H L Neumann; A Jung; T Kirchner
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

6.  Responsiveness of CPT-11 in respect to hMLH1 and hMSH2 protein expression in the primary colorectal cancer.

Authors:  In Ja Park; Hee Cheol Kim; Chang Sik Yu; Heung Moon Chang; Jea Hwan Lee; Jong Hoon Kim; Tae Won Kim; Jung Sun Kim; Jin Cheon Kim
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

Review 7.  Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome.

Authors:  Linnea M Baudhuin; Lawrence J Burgart; Olga Leontovich; Stephen N Thibodeau
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

8.  Aetiology of colorectal cancer and relevance of monogenic inheritance.

Authors:  M Ponz de Leon; P Benatti; F Borghi; M Pedroni; A Scarselli; C Di Gregorio; L Losi; A Viel; M Genuardi; G Abbati; G Rossi; M Menigatti; I Lamberti; G Ponti; L Roncucci
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Economic and Practical Factors in Diagnosing HNPCC Using Clinical Criteria, Immunohistochemistry and Microsatellite Instability Analysis.

Authors:  Francesca Pigatto; Adrian Bateman; David Bunyan; Paul Strike; Esta Wilkins; Claire Curtis; Philippa Duncan; Denzil May; Karen Nugent; Diana Eccles
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

10.  Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer.

Authors:  Sibel Erdamar; Esra Ucaryilmaz; Gokhan Demir; Tayfun Karahasanoglu; Gulen Dogusoy; Ahmet Dirican; Suha Goksel
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.